Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.79 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228913 | 0.91 | DPP4 (0.70) | DPP4DPP8CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14142701 | 0.89 | DPP4 (0.80) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| SCHEMBL389715 | 0.88 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| SCHEMBL2087382 | 0.88 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| SCHEMBL389714 | 0.88 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| SCHEMBL390403 | 0.88 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| SCHEMBL8237899 | 0.87 | DPP4 (0.78) | DPP4DPP8OPRM1OPRK1 | |
| Trelagliptin SCHEMBL175726 | 0.87 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| Trelagliptin SCHEMBL29349599 | 0.87 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 | |
| Trelagliptin SCHEMBL175727 | 0.87 | DPP4 (1.00) | DPP4DPP8OPRM1OPRK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007112368-A1 | PREPARATION OF (R)-3-AMINOPIPERIDINE DIHYDROCHLORIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |